Compare JNJ & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JNJ | NVO |
|---|---|---|
| Founded | 1886 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4B | 199.4B |
| IPO Year | 2003 | 2001 |
| Metric | JNJ | NVO |
|---|---|---|
| Price | $286.29 | $41.51 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 14 |
| Target Price | ★ $279.41 | $45.63 |
| AVG Volume (30 Days) | 6.9M | ★ 8.9M |
| Earning Date | 10-13-2026 | 11-04-2026 |
| Dividend Yield | 1.89% | ★ 3.15% |
| EPS Growth | ★ 90.50 | N/A |
| EPS | ★ 4.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.46 | $0.06 |
| Revenue Next Year | $6.45 | $1.32 |
| P/E Ratio | $63.21 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $195.90 | $35.12 |
| 52 Week High | $286.08 | $64.16 |
| Indicator | JNJ | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 66.21 | 57.17 |
| Support Level | $262.26 | $41.05 |
| Resistance Level | N/A | $43.24 |
| Average True Range (ATR) | 6.76 | 0.83 |
| MACD | 1.63 | 0.25 |
| Stochastic Oscillator | 93.94 | 68.09 |
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.